Introduction to checkpoint inhibitors and cancer immunotherapy-Reference-Cited by-同舟云学术

Introduction to checkpoint inhibitors and cancer immunotherapy

Published:2017-03 Issue:1 Volume:276 Page:5-8
ISSN:0105-2896
Container-title:Immunological Reviews
language:en
Short-container-title:Immunol Rev

Author:

Sharpe Arlene H.¹

Affiliation:

1. Department of Microbiology and Immunobiology, and Evergrande Center for Immunologic Diseases; Harvard Medical School and Brigham and Women's Hospital; Boston MA USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/imr.12531/fullpdf

Reference28 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

2. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab;McDermott;J Clin Oncol,2015

3. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial;Ribas;Lancet Oncol,2015

4. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma;Schadendorf;J Clin Oncol,2015

5. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer;Topalian;N Engl J Med,2012

Cited by 157 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies;Cancers;2024-07-23

2. Alternative activation of mast cells by CD4+ T helper cells;Journal of Leukocyte Biology;2024-06-25

3. Development of small molecule drugs targeting immune checkpoints;Cancer Biology & Medicine;2024-05-09

4. RFA-INDUCED ALTERATIONS IN THE EXPRESSION OF PD-1 AND CTLA-4 IN THE TUMOUR MICROENVIRONMENT pCCA: RESULTS FROM AN EXPLORATORY STUDY;FARMACIA;2024